Thong Q. Le

SENIOR MANAGING DIRECTOR
PRESIDENT & CHIEF EXECUTIVE OFFICER

Thong Q. Le currently serves as Senior Managing Director and CEO of Accelerator.  Mr. Le has over 20 years of experience identifying, investing in, managing, and successfully exiting numerous seed and early-stage investments in the biotechnology sector. He has served as the founding CEO and director of numerous Accelerator Life Science Partners portfolio companies, including Petra Pharma (substantial acquisition by a global pharmaceutical company in May 2020), Rodeo Therapeutics (acquired by Amgen Inc. for up to $721 million in March 2021), and Lodo Therapeutics (acquired by Zymergen in May 2021). He currently oversees the firm’s investments in ALSP ORCHID Acquisition Corporation I (NASDAQ: ALORU | ALOR), Lydian Neurosciences, Magnolia Neurosciences, and Proniras Corporation, where he also serves as CEO and Director of each company.

Prior to joining Accelerator, Mr. Le served as a Managing Director at WRF Capital, the venture capital investment arm of Washington Research Foundation where he played a significant role in the early sourcing, financing, and development of numerous life science companies, including Alder Biopharmaceuticals (NASDAQ: ALDR | acquired by H. Lundbeck A/S), Corus Pharma (acquired by Gilead Sciences), Halosource (LSE: HALO), Hyperion Therapeutics (NASDAQ: HPTX | acquired by Horizon Pharma plc), Lumera (NASDAQ: LMRA), Pathway Medical Technologies (acquired by MEDRAD), and VLST (asset acquisition by major international pharmaceutical company). Prior to joining WRF Capital, Mr. Le was the founder, president and CEO of MiniMeals, Inc. and a consultant for Capital Management Consulting, Inc. Earlier, he was at Raymond James & Associates, Singer & Xenos Investment Management Company and Capital Management Group LLC, a private investment firm specializing in biomedical ventures.

Mr. Le completed post-graduate studies at the Templeton College of Oxford University and received his A.B. cum laude in Government from Harvard University. He serves on the advisory board for the Alexandria Seed Capital Platform and on the boards of Acylin Therapeutics, Briotech, and Ravenna Pharmaceuticals. He was previously named one of the region’s “40 Under 40” by the Puget Sound Business Journal.